Table 3.
Tumor and patient characteristics. N; lymph node status, NHG; Nottingham Histologic Grade, PR; progesterone receptor, ROR; risk of recurrence score. * Ki67 pathology lab specific limits are presented in Table 1.
| n/Mean | %/Range | |
|---|---|---|
| Age average (years) | 65.1 | (41–84) |
| Tumor size (mm) | 19.4 | (6–60) |
| N0 | 358 | 99.4% |
| N+ | 2 | 0.6% |
| Micrometastasis | 4 | 1.1% |
| Tumor grade | ||
| NHG 1 | 12 | 3% |
| NHG 2 | 285 | 79% |
| NHG 3 | 62 | 17% |
| Ki67 (average) | 27.7% | (2–90) |
| Low * | 27 | 7.5% |
| Intermediate * | 99 | 27.5% |
| High * | 234 | 65.0% |
| PgR | 58.2% | 0–100 |
| ≥20% | 274 | 76% |
| <20% | 86 | 24% |
| PAM50 Prosigna | ||
| LumA | 210 | 58.3% |
| LumB | 145 | 40.3% |
| HER2-enriched | 3 | 0.8% |
| ROR score | 44 | 0–86 |
| low risk (ROR 0–40) | 146 | 40.6% |
| intermediate risk (ROR 41–60) | 153 | 42.5% |
| high risk (ROR 60–100) | 56 | 15.6% |